The market for cholesterol lowering drugs is expected to grow at a CAGR of around 7.1% from 2020 to 2027 and expected to reach the market value of around US$ 27.5 Bn by 2027.
Cholesterol-Lowering Drugs, Hypolipidemic agents, or antihyperlipidemic agents are used for the treatment of high levels of fats (lipids), such as cholesterol, in the blood (hyperlipidemia). These are also known as lipid-lowering drugs. The high level of cholesterol leads to heart attacks, stroke, and may cause death from heart disease. According to a study held at Harvard, taking a statin cuts overall cardiovascular risk by 20% to nearly 50%. According to the Centers for Disease Control and Prevention (CDC) database of 2017, more than 365,914 people have died in the United States due to coronary artery disease, and about 18.2 million adults aged 20 years and older have coronary artery disease.
Market Dynamics
The growing awareness about bad cholesterol and investigational studies held by companies to understand which drugs are well-tolerated in patients to make improvements according to the results are the primary factors driving the market growth. The increasing research activities to include bempedoic acid for the development of new drugs, healthcare providers are recommending the intake of bempedoic acid with statins to lower complications of LDL (Low-density Lipoproteins) associated with hypercholesterolemia are bolstering the market growth. The companies are harnessing the advantages of bempedoic acid to treat a host of health conditions like hypercholesterolemia as well as to treat patients with high cardiovascular disease (CVD) risks are accelerating the market growth.
On the other side, severe side effects of statins causing rhabdomyolysis and availability of generic drugs of major leading brands are anticipated to hinder the growth during the forecast period.
Segment Instance
Some of the leading drugs under the statins and fixed-dose combination segment include crestor, lipitor, livalo, lescol/lescol XL, zocor, vytorin, caduet, and others. The cholesterol absorption inhibitors, ion exchange resins, and fibrates segment include zetia, welchol, tricor, and others. The PCSK9 Inhibitor segment includes praluent, repatha, RN316, and others. Additionally, the novel cholesterol-lowering drugs segment includes juxtapid, kynamro, MK-0859, and others.
Retail Pharmacies accounted for the major revenue share in the Cholesterol Lowering Drugs Market
Based on the distribution channel, retail pharmacies are the leading segment in terms of revenue and volume both as the people used to buy due to convenience. Additionally, people are more likely to buy the prescribed medication from a reliable and better access store. Moreover, online pharmacies are likely to experience the fastest growth throughout the forecast timeframe from 2020 to 2027. The increasing number of online stores coupled with the increasing number of online buyers, especially in developing economies is projected to create potential demand over the forecast period from the online pharmacies. The increasing number of startups, which are offerings discounts and delivering medicines to the consumers at the time, as well as offering cash on delivery feature which is creating reliability on online pharmacies, are some of the factors driving the segmental market growth.
Key Market Players
The players profiled in the report include AbbVie, Inc. (US), Amgen (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Novartis AG (Switzerland), Pfizer, Inc. (US), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), and others.
Market Segmentation
Market By Drug Class
Cholesterol Absorption Inhibitors
Fibrates
Fixed-Dose Combinations
Ion Exchange Resins
Novel Cholesterol-Lowering Drugs
PCSK9 Inhibitors
Statins
Market By Disease Type
Hypercholesterolemia
Cardiovascular Diseases
Hyperlipidemia
Market By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Market By Geography
North America
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
CHAPTER 1. Industry Overview of Cholesterol Lowering Drugs
1.1. Definition and Scope
1.1.1. Definition of Cholesterol Lowering Drugs
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Cholesterol Lowering Drugs Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Cholesterol Lowering Drugs Market By Drug Class
1.2.3. Cholesterol Lowering Drugs Market By Disease Type
1.2.4. Cholesterol Lowering Drugs Market By Distribution Channel
1.2.5. Cholesterol Lowering Drugs Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Cholesterol Lowering Drugs Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Cholesterol Lowering Drugs Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Application Source of Cholesterol Lowering Drugs Major Manufacturers in 2019
CHAPTER 5. Cholesterol Lowering Drugs Market By Drug Class
5.1. Introduction
5.2. Cholesterol Lowering Drugs Revenue By Drug Class
5.2.1. Cholesterol Lowering Drugs Revenue (US$ Mn) and Forecast, By Drug Class, 2016-2027
5.2.2. Cholesterol Absorption Inhibitors
5.2.2.1. Cholesterol Absorption Inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Fibrates
5.2.3.1. Fibrates Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.4. Fixed-Dose Combinations
5.2.4.1. Fixed-Dose Combinations Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.5. Ion Exchange Resins
5.2.5.1. Ion Exchange Resins Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.6. Novel Cholesterol-Lowering Drugs
5.2.6.1. Novel Cholesterol-Lowering Drugs Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.7. PCSK9 Inhibitors
5.2.7.1. PCSK9 Inhibitors Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.8. Statins
5.2.8.1. Statins Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. Cholesterol Lowering Drugs Market Revenue By Disease Type
6.1. Introduction
6.2. Cholesterol Lowering Drugs Revenue (US$ Mn) By Disease Type
6.2.1. Cholesterol Lowering Drugs Revenue (US$ Mn) and Forecast By Disease Type, 2016 - 2027
6.2.2. Hypercholesterolemia
6.2.2.1. Hypercholesterolemia Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. Cardiovascular Diseases
6.2.3.1. Cardiovascular Diseases Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.4. Hyperlipidemia
6.2.4.1. Hyperlipidemia Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 7. Cholesterol Lowering Drugs Market By Distribution Channel
7.1. Introduction
7.2. Cholesterol Lowering Drugs Revenue (US$ Mn) By Distribution Channel
7.2.1. Cholesterol Lowering Drugs Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
7.2.2. Retail Pharmacies
7.2.2.1. Retail Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.3. Hospital Pharmacies
7.2.3.1. Hospital Pharmacies
7.2.4. Online Pharmacies
7.2.4.1. Online Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 8. North America Cholesterol Lowering Drugs Market By Country
8.1. North America Cholesterol Lowering Drugs Overview
8.2. U.S.
8.2.1. U.S. Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
8.2.2. U.S. Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016-2027
8.2.3. U.S. Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
8.3. Canada
8.3.1. Canada Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
8.3.2. Canada Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016-2027
8.3.3. Canada Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
8.4. North America PEST Analysis
CHAPTER 9. Europe Cholesterol Lowering Drugs Market By Country
9.1. Europe Cholesterol Lowering Drugs Market Overview
9.2. U.K.
9.2.1. U.K. Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.2.2. U.K. Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016-2027
9.2.3. U.K. Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
9.3. Germany
9.3.1. Germany Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.3.2. Germany Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016-2027
9.3.3. Germany Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
9.4. France
9.4.1. France Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.4.2. France Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016-2027
9.4.3. France Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
9.5. Spain
9.5.1. Spain Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.5.2. Spain Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016-2027
9.5.3. Spain Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
9.6. Rest of Europe
9.6.1. Rest of Europe Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016-2027
9.6.2. Rest of Europe Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016-2027
9.6.3. Rest of Europe Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Cholesterol Lowering Drugs Market By Country
10.1. Asia Pacific Cholesterol Lowering Drugs Market Overview
10.2. China
10.2.1. China Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.2.2. China Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016 - 2027
10.2.3. China Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.3. Japan
10.3.1. Japan Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.3.2. Japan Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016 - 2027
10.3.3. Japan Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.4. India
10.4.1. India Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.4.2. India Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016 - 2027
10.4.3. India Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.5. Australia
10.5.1. Australia Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.5.2. Australia Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016 - 2027
10.5.3. Australia Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.6. South Korea
10.6.1. South Korea Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.6.2. South Korea Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016 - 2027
10.6.3. South Korea Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
10.7.2. Rest of Asia-Pacific Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016 - 2027
10.7.3. Rest of Asia-Pacific Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Cholesterol Lowering Drugs Market By Country
11.1. Latin America Cholesterol Lowering Drugs Market Overview
11.2. Brazil
11.2.1. Brazil Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
11.2.2. Brazil Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016 - 2027
11.2.3. Brazil Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.3. Mexico
11.3.1. Mexico Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
11.3.2. Mexico Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016 - 2027
11.3.3. Mexico Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.4. Rest of Latin America
11.4.1. Rest of Latin America Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
11.4.2. Rest of Latin America Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016 - 2027
CHAPTER 12. Middle East & Africa Cholesterol Lowering Drugs Market By Country
12.1. Middle East & Africa Cholesterol Lowering Drugs Market Overview
12.2. Saudi Arabia
12.2.1. Saudi Arabia Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
12.2.2. Saudi Arabia Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016 - 2027
12.2.3. Saudi Arabia Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
12.3. UAE
12.3.1. UAE Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
12.3.2. UAE Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016 - 2027
12.3.3. UAE Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Drug Class, 2016 - 2027
12.4.2. Rest of Middle East & Africa Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Disease Type, 2016 - 2027
12.4.3. Rest of Middle East & Africa Cholesterol Lowering Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
CHAPTER 13. Player Analysis Of Cholesterol Lowering Drugs
13.1. Cholesterol Lowering Drugs Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Cholesterol Lowering Drugs Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. COMPANY PROFILE
14.1. AbbVie, Inc. (US)
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (US$ Mn), 2019
14.1.3.2. AbbVie, Inc. (US) 2019 Cholesterol Lowering Drugs Business Regional Distribution
14.1.4. Product/ Service and Specification
14.1.5. Recent Developments & Business Strategy
14.1.6. Manufacturing Plant Footprint Analysis
14.2. Amgen (US)
14.3. GlaxoSmithKline plc (UK)
14.4. Merck & Co., Inc. (US)
14.5. Novartis AG (Switzerland)
14.6. Pfizer, Inc. (US)
14.7. Sanofi (France)
14.8. Sun Pharmaceutical Industries Ltd. (India)
14.9. Takeda Pharmaceutical Company Limited (Japan)
14.10. Others
